Some major changes have taken place at the top of Belgian biopharma ASIT biotech (EBR: ASIT).
Michel Baijot has taken over as chief executive of the company, which is trying to come to a fair arrangement with his predecessor Thierry Legon ‘with the objective that this termination has a limited financial impact’, an ASIT statement said.
Yves Désiront is interim chief financial officer, while the company seeks a replacement for Everard van der Straten, who supervised the financial organization of the company and its financing since its IPO in 2016, and will remain a board member.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze